Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Celgene Corporation |
---|---|
Information provided by: | Celgene Corporation |
ClinicalTrials.gov Identifier: | NCT00045786 |
The primary objective of the study is to assess the safety of CC-1088 to patients with myelodysplastic syndromes (MDS).
Condition | Intervention | Phase |
---|---|---|
Myelodysplastic Syndrome |
Drug: CC-1088 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study |
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Study ID Numbers: | CC-1088-MDS-801-001 |
Study First Received: | September 9, 2002 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00045786 |
Health Authority: | United States: Food and Drug Administration |
myelodysplastic syndrome |
Myelodysplastic syndromes Preleukemia Precancerous Conditions Hematologic Diseases |
Myelodysplasia Myelodysplastic Syndromes Bone Marrow Diseases |
Neoplasms Pathologic Processes Disease Syndrome |